enVVeno Medical
NVNO· Manufacturing· Fiscal year ends in December
CEO pay in FY2024Stock -41.2% in FY2024
Robert A. Berman is the CEO of enVVeno Medical and was paid $1.2M in FY2024 (Dec), down 38%.
Pay$100 in the stock at the end of FY21 → $46
Executives5
See all- 1Robert A. BermanChief Executive OfficerFY2024
- 2Marc H. Glickman, M.D.Chief Medical Officer and Senior Vice PresidentFY2023
- 3Dr. Hamed AlaviSenior Vice President & Chief Technology OfficerFY2023
- 4Craig GlynnFormer Chief Financial OfficerFY2023
- 5Jennifer BrightChief Financial OfficerFY2024
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allenVVeno Medical paid its 2 named executives $1.2M in total in FY2024 (Dec). CEO Robert A. Berman was paid $1.2M of that.
| Name | |||
|---|---|---|---|
| Robert A. BermanChief Executive Officer | |||
| Jennifer BrightChief Financial Officer | Not disclosed | Not disclosed | |
| Marc H. Glickman, M.D.Chief Medical Officer and Senior Vice President | Not disclosed | ||
| Dr. Hamed AlaviSenior Vice President & Chief Technology Officer | Not disclosed | ||
| Craig GlynnFormer Chief Financial Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for enVVeno Medical. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board2
See all- Sanjay ShrivastavaDirector · 7 yr on the boardIndependentAudit, Compensation, Nominating and Corporate Governance—Paid as an executive
- Matthew M. JenusaitisDirector · 6 yr on the boardIndependentAudit, Compensation, Nominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Oct 29, 2026 | FY2025 |
| Annual report | 10-K | Mar 26, 2026 | FY2025 |
| Proxy statement | DEF 14A | Oct 30, 2025 | FY2024 |
| Annual report | 10-K | Feb 28, 2025 | FY2024 |
| Proxy statement | DEF 14A | Nov 19, 2024 | FY2023 |
| Annual report | 10-K | Feb 29, 2024 | FY2023 |
